Quantcast
Home > Quotes > CBAY
CBAY

CymaBay Therapeutics Inc. Common Stock (CBAY) Quote & Summary Data

$8.66
*  
0.01
0.12%
Get CBAY Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading CBAY now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
20
Today's High / Low
$ 8.90 / $ 8.44
Share Volume
337,950
50 Day Avg. Daily Volume
560,645
Previous Close
$ 8.65
52 Week High / Low
$ 15.59 / $ 7.37
Market Cap
514,742,866
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.07
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.33

Intraday Chart

Shares Traded

Share Volume:
337,950
50 Day Avg. Daily Volume:
560,645

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.07

Trading Range

The current last sale of $8.66 is 17.50% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.90 $ 15.59
 Low: $ 8.44 $ 7.37

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Our lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPAR ?), a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. We are currently developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver. We are also planning to develop seladelpar for the treatment of nonalcoholic steatohepatitis (NASH), a prevalent and serious chronic liver disease caused by excessive fat accumulation in the liver that results in inflammation and cellular injury that can progress to fibrosis and cirrhosis, and potentially liver failure and death.  ... More ...  


Risk Grade

Where does CBAY fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.58
Open Date:
Dec. 14, 2018
Close Price:
$ 8.66
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info